business

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Forbes · Jun 9, 2026, 1:00 PM · Also reported by 3 other sources

Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.

Read full story on Forbes → More top stories

Also covered by

ABC Australia Doctors call for mandatory food star ratings to stop health 'crisis' MIT Technology Review David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition The Hindu FIFA World Cup 2026: Argentina squad closer to full health ahead of opener

Aggregated and edited by the Scoop newsroom. We surface news from Forbes alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Also covered by

More in business